Adalimumab for Crohn's disease after infliximab treatment failure: A systematic review

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 8, 2013, Pages 885-891

  Da, Wei ^a   Zhu, Jinshui ^a   Wang, Long ^a   Lu, Yunmin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Antibody; efficacy; tumor necrosis factor

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

CROHN DISEASE; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEVER; HUMAN; INJECTION SITE IRRITATION; INJECTION SITE PAIN; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; DRUG SUBSTITUTION; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATION MEDIATORS; REMISSION INDUCTION; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879982331     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32836220ab     Document Type: Review

References (26)

1. Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1998; 114:1161-1168.
2. Loftus CG, Loftus EVJr., Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ 3rd, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007; 13:254-261.
3. Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5:1424-1429.
4. Wilkins T, Jarvis K, Patel J. Diagnosis and management of Crohn's disease. Am Fam Physician 2011; 84:1365-1375.
5. Buchner AM, Blonski W, Lichtenstein GR. Update on the management of Crohn's disease. Curr Gastroenterol Rep 2011; 13:465-474.
6. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008; 1:CD006893.
7. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:644-659, quiz 660.
8. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348:601-608.
9. Bain B, Brazil M. Adalimumab. Nat Rev Drug Discov 2003; 2:693-694.
10. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, Mac Intosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130:323-333, quiz 591.
11. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132:52-65.
12. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, Mac Intosh DG, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56:1232-1 239.
13. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146:829-838.
14. Ma C, Panaccione R, Heitman SJ, Devlin SM, Ghosh S, Kaplan GG. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment Pharmacol Ther 2009; 30:977-986.
15. Youdim A, Vasiliauskas EA, Targan SR, Papadakis KA, Ippoliti A, Dubinsky MC, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004; 10:333-338.
16. Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007; 25:675-680.
17. Hinojosa J, Gomollon F, Garcia S, Bastida G, Cabriada JL, Saro C, et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007; 25:409-418.
18. Sandborn WJ, Hanauer S, Loftus EVJr, Tremaine WJ, Kane S, Cohen R, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004; 99:1984-1989.
19. Papadakis KA, Shaye OA, Vasiliauskas EA, Ippoliti A, Dubinsky MC, Birt J, et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005; 100:75-79.
20. Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, et al. Adalimumab in patients with Crohn's disease-safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 2007; 25: 787-796.
21. Echarri A, Castro J, Barreiro M, Carpio D, Pereira S, Lorenzo A. Evaluation of adalimumabtherapy in multidisciplinary strategy for perianal Crohn'sdisease patients with infliximab failure. J Crohns Colitis 2010; 4:654-660.
22. Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010; 32:1228-1239.
23. Cordero Ruiz P, Castro Marquez C, Mendez Rufian V, Castro Laria L, Caunedo Alvarez A, Romero Vázquez J, et al. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series. Rev Esp Enferm Dig 2011; 103:294-298.
24. Lofberg R, Louis EV, Reinisch W, Robinson AM, Kron M, Camez A, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis 2012; 18:1-9.
25. Panaccione R, Loftus EV Jr, Binion D, Mc Hugh K, Alam S, Chen N, et al. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian Subje Cts with Mod Erate to Severe Crohn's Disea Se (ACCESS) trial. Can J Gastroenterol 2011; 25:419-425.
26. Bachmann F, Nast A, Sterry W, Philipp S. Safety and efficacy of the tumor necrosis factor antagonists. Semin Cutan Med Surg 2010; 29:35-47.